---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-001408"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T08:23:44.536395+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma reports LYMPHIR launch prep progress; targeting H1 2025 commercial launch

## Summary
- LYMPHIR approved Aug 2024 for relapsed/refractory CTCL; commercial launch targeted H1 2025.
- Secured commercial supply agreements with CMOs; first-year launch supply already produced.
- Submitted J-code application under HCPCS; secured inclusion in NCCN guidelines.
- Designing patient assistance program and building specialized sales team for CTCL providers.
- Exploring international licensing partnerships and expanded indications, including combination immunotherapy.

## SEC filing metadata
- accession: 0001213900-25-001408
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390025001408/0001213900-25-001408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390025001408/ea0226990-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-001408
- JSON: https://secwatch.observer/filing/0001213900-25-001408.json
- Plain text: https://secwatch.observer/filing/0001213900-25-001408.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.